Literature DB >> 18330777

Ethnic neutropenia and clozapine.

Amanda Bray1.   

Abstract

OBJECTIVES: The aim of the present paper was to examine the concept of benign ethnic neutropenia and to consider the implications of ethnicity in the current clozapine regulatory system.
METHOD: The case of a young Palestinian man who lost access to clozapine due to a fall in his neutrophil count, is presented herein, and a brief review of ethnic variations in neutrophil levels is given.
RESULTS: This patient's clozapine was ceased, with unfortunate consequences, despite his having normal immune function.
CONCLUSION: By using normative haematological data established in white populations, the Australian clozapine regulatory system places some non-white patients at a considerable disadvantage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18330777     DOI: 10.1080/00048670701881595

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  3 in total

Review 1.  Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports.

Authors:  Memduha Aydin; Bilge Cetin Ilhan; Saliha Calisir; Seda Yildirim; Ibrahim Eren
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

2.  Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.

Authors:  Charles M Richardson; Erica A Davis; Gopal R Vyas; Bethany A DiPaula; Robert P McMahon; Deanna L Kelly
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

Review 3.  When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

Authors:  Peter Manu; Deepak Sarpal; Owen Muir; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2011-11-22       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.